描述 |
DY131(GSK 9089)是ERRβ和ERRγ选择性激动剂,对ERRα,ERα和ERβ的活性极低。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
DMSO:50 mg / mL(160.58 mM;需要超声波) 体内:1。逐个添加每种溶剂:10%DMSO 40%PEG300 5%吐温-80 45%盐水溶解度:≥2.5mg/ mL(8.03mM);澄清溶液2.逐个添加每种溶剂:10%DMSO 90%玉米油溶解度:≥2.5mg / mL(8.03 mM);悬浮液3.逐个加入各溶剂:10%DMSO 90%(20%SBE-β-CD在盐水中)溶解度:≥2.5mg / mL(8.03 mM);明确解决方案
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
O=C(N/N=C/C1=CC=C(N(CC)CC)C=C1)C2=CC=C(O)C=C2 |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
Elacestrant dihydrochloride | AZD9496 | 山奈酚 | 3-[4-[[2,4-二(三氟甲基)苄基]氧基]-3-甲氧基苯基]-2-氰基-N-(5-三氟甲基-[1,3,4]噻二唑-2-基)丙烯酰胺 | 雌酚酮 | Brilanestrant | 原人参三醇 | 27-羟基胆固醇 | 己烯雌酚 | PHTPP | 2,3-双(4-羟苯基)丙腈 | 雌马酚 | 胆固醇 | 5,7-二羟黄酮 | Endoxifen Z-异构体盐酸盐 |
密度 | 1.1±0.1 g/cm3 |
---|---|
分子式 | C18H21N3O2 |
分子量 | 311.378 |
精确质量 | 311.163391 |
PSA | 64.93000 |
LogP | 3.17 |
折射率 | 1.574 |
~66%
DY131
95167-41-2
|
文献:Forman, Barry; Yu, Donna Patent: US2006/189825 A1, 2006 ; Location in patent: Page/Page column 7; 12; Sheet 3/7 ; US 20060189825 A1 |
~%
DY131
95167-41-2
|
文献:Bioorganic and Medicinal Chemistry Letters, , vol. 15, # 5 p. 1311 – 1313 |
~%
DY131
95167-41-2
|
文献:Bioorganic and Medicinal Chemistry Letters, , vol. 15, # 5 p. 1311 – 1313 |
~%
DY131
95167-41-2
|
文献:Journal of Medicinal Chemistry, , vol. 48, # 9 p. 3107 – 3109 |
DY131上游产品? 4 | |
---|---|
|
|
DY131下游产品? 0 |
海关编码 | 2928000090 |
---|---|
中文概述 | 2928000090 其他肼(联氨)及胲(羟胺)的有机衍生物。监管条件:无。增值税率:17.0%。退税率:9.0%。最惠国关税:6.5%。普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途 |
Summary | 2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
Benzoic acid, 4-hydroxy-, 2-[(1E)-[4-(diethylamino)phenyl]methylene]hydrazide |
N’-{(E)-[4-(diethylamino)phenyl]methylidene}-4-hydroxybenzohydrazide |
N’-{(E)-[4-(Diethylamino)phenyl]methylene}-4-hydroxybenzohydrazide |
Benzoic acid, 4-hydroxy-, [[4-(diethylamino)phenyl]methylene]hydrazide (9CI) |
N-(4-(Diethylaminobenzylidenyl)-N’-(4-hydroxybenzoyl)-hydrazine |
GSK 9089 |